Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 12.00
ALXN's Cash to Debt is ranked lower than
57% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. ALXN: 12.00 )
ALXN' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 12

Equity to Asset 0.80
ALXN's Equity to Asset is ranked higher than
67% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALXN: 0.80 )
ALXN' s 10-Year Equity to Asset Range
Min: 0.04   Max: 0.95
Current: 0.8

0.04
0.95
Interest Coverage 291.32
ALXN's Interest Coverage is ranked lower than
82% of the 382 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 291.32 )
ALXN' s 10-Year Interest Coverage Range
Min: 14.38   Max: 9999.99
Current: 291.32

14.38
9999.99
F-Score: 6
Z-Score: 24.99
M-Score: -2.50
WACC vs ROIC
11.00%
39.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 33.65
ALXN's Operating margin (%) is ranked higher than
93% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. ALXN: 33.65 )
ALXN' s 10-Year Operating margin (%) Range
Min: -10370.21   Max: 38.89
Current: 33.65

-10370.21
38.89
Net-margin (%) 25.97
ALXN's Net-margin (%) is ranked higher than
90% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. ALXN: 25.97 )
ALXN' s 10-Year Net-margin (%) Range
Min: -10220.86   Max: 76.31
Current: 25.97

-10220.86
76.31
ROE (%) 18.97
ALXN's ROE (%) is ranked higher than
92% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. ALXN: 18.97 )
ALXN' s 10-Year ROE (%) Range
Min: -136.75   Max: 63.11
Current: 18.97

-136.75
63.11
ROA (%) 15.15
ALXN's ROA (%) is ranked higher than
93% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. ALXN: 15.15 )
ALXN' s 10-Year ROA (%) Range
Min: -45.22   Max: 46.71
Current: 15.15

-45.22
46.71
ROC (Joel Greenblatt) (%) 113.47
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. ALXN: 113.47 )
ALXN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -963.15   Max: 172.59
Current: 113.47

-963.15
172.59
Revenue Growth (3Y)(%) 39.50
ALXN's Revenue Growth (3Y)(%) is ranked higher than
89% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ALXN: 39.50 )
ALXN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.5   Max: 498.1
Current: 39.5

-70.5
498.1
EBITDA Growth (3Y)(%) 52.40
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. ALXN: 52.40 )
ALXN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.1   Max: 72.8
Current: 52.4

-10.1
72.8
EPS Growth (3Y)(%) 53.00
ALXN's EPS Growth (3Y)(%) is ranked higher than
93% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. ALXN: 53.00 )
ALXN' s 10-Year EPS Growth (3Y)(%) Range
Min: -15.3   Max: 77.3
Current: 53

-15.3
77.3
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ALXN Guru Trades in Q2 2014

Jim Simons 245,552 sh (New)
Joel Greenblatt 17,094 sh (+240.11%)
Andreas Halvorsen 2,006,092 sh (+9.23%)
Pioneer Investments 31,934 sh (+1.53%)
Frank Sands 5,279,782 sh (+0.22%)
Steven Cohen 11,700 sh (unchged)
John Burbank Sold Out
Ron Baron 10,145 sh (-0.71%)
Ray Dalio 26,332 sh (-47.72%)
Paul Tudor Jones 1,326 sh (-76.84%)
» More
Q3 2014

ALXN Guru Trades in Q3 2014

Paul Tudor Jones 3,120 sh (+135.29%)
Ron Baron 12,941 sh (+27.56%)
Andreas Halvorsen 2,198,451 sh (+9.59%)
Frank Sands 5,311,488 sh (+0.60%)
Pioneer Investments 30,500 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Jim Simons 206,152 sh (-16.05%)
Joel Greenblatt 1,804 sh (-89.45%)
» More
Q4 2014

ALXN Guru Trades in Q4 2014

Ray Dalio 18,513 sh (New)
Joel Greenblatt 85,974 sh (+4665.74%)
Ron Baron 18,366 sh (+41.92%)
Pioneer Investments 30,795 sh (+0.97%)
Frank Sands 5,267,903 sh (-0.82%)
Frank Sands 5,267,903 sh (-0.82%)
Jim Simons 152,552 sh (-26.00%)
Paul Tudor Jones 1,487 sh (-52.34%)
Andreas Halvorsen 390,271 sh (-82.25%)
» More
Q1 2015

ALXN Guru Trades in Q1 2015

Lee Ainslie 1,350 sh (New)
Ron Baron 41,163 sh (+124.13%)
Paul Tudor Jones 3,231 sh (+117.28%)
Jim Simons 313,952 sh (+105.80%)
Ray Dalio 29,099 sh (+57.18%)
Pioneer Investments 31,941 sh (+3.72%)
Andreas Halvorsen Sold Out
Frank Sands 5,204,296 sh (-1.21%)
Joel Greenblatt 23,261 sh (-72.94%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Alexion Pharmaceuticals Inc

Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Alexion Pharmaceuticals Inc, Equity Residential, and Tableau Software Inc. Read more...
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY
According to GuruFocus Insider Data, the largest insider sells during the past week were: Oracle Corporation (ORCL), Alexion Pharmaceuticals Inc (ALXN), Waters Corp (WAT) and DENTSPLY International Inc (XRAY). Read more...
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock
The CEO of Alexion Pharmaceuticals Inc (ALXN), Leonard Bell, sold more than 100,000 shares of company stock Wednesday for nearly $17 million. At a price of $160.71 per share, the sale of 105,000 shares of company stock brought $16,874,551. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 56.80
ALXN's P/E(ttm) is ranked lower than
78% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 32.00 vs. ALXN: 56.80 )
ALXN' s 10-Year P/E(ttm) Range
Min: 13.92   Max: 1113.68
Current: 56.8

13.92
1113.68
Forward P/E 25.32
ALXN's Forward P/E is ranked lower than
65% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ALXN: 25.32 )
N/A
PE(NRI) 58.90
ALXN's PE(NRI) is ranked lower than
64% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 38.20 vs. ALXN: 58.90 )
ALXN' s 10-Year PE(NRI) Range
Min: 13.96   Max: 1058
Current: 58.9

13.96
1058
P/B 9.50
ALXN's P/B is ranked lower than
113% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. ALXN: 9.50 )
ALXN' s 10-Year P/B Range
Min: 1.73   Max: 162.14
Current: 9.5

1.73
162.14
P/S 14.76
ALXN's P/S is ranked lower than
78% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: 7.28 vs. ALXN: 14.76 )
ALXN' s 10-Year P/S Range
Min: 9.66   Max: 1115.3
Current: 14.76

9.66
1115.3
PFCF 64.70
ALXN's PFCF is ranked lower than
103% of the 149 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 64.70 )
ALXN' s 10-Year PFCF Range
Min: 40   Max: 99999999.99
Current: 64.7

40
99999999.99
POCF 49.98
ALXN's POCF is ranked lower than
65% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 31.11 vs. ALXN: 49.98 )
ALXN' s 10-Year POCF Range
Min: 33.16   Max: 83.87
Current: 49.98

33.16
83.87
EV-to-EBIT 42.67
ALXN's EV-to-EBIT is ranked lower than
60% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 29.86 vs. ALXN: 42.67 )
ALXN' s 10-Year EV-to-EBIT Range
Min: -98.6   Max: 893.9
Current: 42.67

-98.6
893.9
PEG 1.13
ALXN's PEG is ranked higher than
78% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. ALXN: 1.13 )
ALXN' s 10-Year PEG Range
Min: 0.68   Max: 2.63
Current: 1.13

0.68
2.63
Shiller P/E 104.50
ALXN's Shiller P/E is ranked lower than
122% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 32.70 vs. ALXN: 104.50 )
ALXN' s 10-Year Shiller P/E Range
Min: 99.43   Max: 655.33
Current: 104.5

99.43
655.33
Current Ratio 4.92
ALXN's Current Ratio is ranked higher than
54% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ALXN: 4.92 )
ALXN' s 10-Year Current Ratio Range
Min: 1.38   Max: 52.92
Current: 4.92

1.38
52.92
Quick Ratio 4.61
ALXN's Quick Ratio is ranked higher than
54% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. ALXN: 4.61 )
ALXN' s 10-Year Quick Ratio Range
Min: 1.38   Max: 52.92
Current: 4.61

1.38
52.92
Days Inventory 264.48
ALXN's Days Inventory is ranked lower than
84% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 115.80 vs. ALXN: 264.48 )
ALXN' s 10-Year Days Inventory Range
Min: 202.61   Max: 959.95
Current: 264.48

202.61
959.95
Days Sales Outstanding 77.25
ALXN's Days Sales Outstanding is ranked lower than
60% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. ALXN: 77.25 )
ALXN' s 10-Year Days Sales Outstanding Range
Min: 70.74   Max: 451.45
Current: 77.25

70.74
451.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 32.30
ALXN's Price/Net Cash is ranked lower than
143% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ALXN: 32.30 )
ALXN' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 205.55
Current: 32.3

1.37
205.55
Price/Net Current Asset Value 22.50
ALXN's Price/Net Current Asset Value is ranked lower than
129% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ALXN: 22.50 )
ALXN' s 10-Year Price/Net Current Asset Value Range
Min: 1.34   Max: 2321.5
Current: 22.5

1.34
2321.5
Price/Tangible Book 12.40
ALXN's Price/Tangible Book is ranked lower than
133% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 12.40 )
ALXN' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 34.74
Current: 12.4

1.5
34.74
Price/DCF (Projected) 4.60
ALXN's Price/DCF (Projected) is ranked lower than
88% of the 151 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. ALXN: 4.60 )
ALXN' s 10-Year Price/DCF (Projected) Range
Min: 4.34   Max: 142.19
Current: 4.6

4.34
142.19
Price/Median PS Value 0.80
ALXN's Price/Median PS Value is ranked higher than
70% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ALXN: 0.80 )
ALXN' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 56.1
Current: 0.8

0.36
56.1
Price/Peter Lynch Fair Value 2.30
ALXN's Price/Peter Lynch Fair Value is ranked lower than
73% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 2.30 )
ALXN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 4.22
Current: 2.3

0.56
4.22
Price/Graham Number 5.60
ALXN's Price/Graham Number is ranked lower than
97% of the 187 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALXN: 5.60 )
ALXN' s 10-Year Price/Graham Number Range
Min: 2.04   Max: 22.85
Current: 5.6

2.04
22.85
Earnings Yield (Greenblatt) 2.30
ALXN's Earnings Yield (Greenblatt) is ranked higher than
82% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ALXN: 2.30 )
ALXN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3
Current: 2.3

0.1
3
Forward Rate of Return (Yacktman) 50.62
ALXN's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 14.93 vs. ALXN: 50.62 )
ALXN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.5   Max: 75.6
Current: 50.62

-18.5
75.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AXP.Germany, 0QZM.UK, ALXN.Switzerland,
Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.
» More Articles for ALXN

Headlines

Articles On GuruFocus.com
Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 

More From Other Websites
Summer stock picks May 22 2015
A Beautiful Biotech Summer? May 22 2015
Pall-Danaher Transaction: What You Should Know about Danaher May 21 2015
Pall-Danaher Transaction: An Overview of Pall May 21 2015
Achillion Dives As J&J Hep C Deal Chills Buyout Buzz May 20 2015
Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J May 20 2015
Do R&D Costs Matter When It Comes To Drug Pricing? May 20 2015
Should You Set Up the Synageva BioPharma–Alexion Spread? May 14 2015
Platinum picks for your portfolio May 14 2015
Alexion Pharmaceuticals: A Focus on Treating Rare Disorders May 13 2015
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 12 2015
The Synageva–Alexion Merger: Stock and Cash Considerations May 12 2015
Alexion Pharmaceuticals Pays up to Get Synageva BioPharma May 12 2015
Disruptor 50: No.1 Moderna Therapeutics May 12 2015
A hot biotech that may be the next Genentech May 12 2015
Alexion to Present at Investor Conferences May 11 2015
SYNAGEVA BIOPHARMA CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout May 08 2015
Jobs report saves Dow, S&P 500 from losses May 08 2015
2 reasons we're not in biotech bubble: Pro May 08 2015
Jobless Claims Are Driven by Technology: XLK Up and QQQ Gains May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK